Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

[Problem] To activate an abnormal mesenchymal stem cell whose therapeutic effect is lost or reduced, or rather which has a disease-exacerbating effect so as to be in a state suitable for cell transplant therapy. [Solution] An activator for mesenchymal stem cells, mesenchymal stem cells activated by the activator, a method for producing the same, and a pharmaceutical containing the activated mesenchymal stem cells are provided.

Provided here, amongst other things, are populations of expanded and stimulated natural killer cells, pharmaceutical compositions comprising populations of expanded and stimulated natural killer cells, and methods of expanding and stimulating natural killer cells

This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

The present invention relates to a method for in vitro cultivation of hematopoietic and/or mesenchymal cells, wherein said cells are cultivated in a cultivation medium comprising gamma-aminobutyric acid (GABA) or a GABA receptor agonist, to cells obtained by such a method and therapeutic use of such cells in methods of treatment of autoimmune, inflammatory or allergic disorder. The invention further relates to pharmaceutical compositions comprising the cells and cultivation media for use in the method according to the invention.

Provided herein are methods of using tissue culture plastic-adherent placental adherent cells, e.g. placental stem cells, referred to herein as placental adherent cells, to treat lymphedema and lymphedema-related disorders.

Described herein are systems, devices, and methods for an extracorporeal, artificial, placenta. In some embodiments, an artificial placenta and amniotic bed system may comprise a control unit, a gas delivery unit, a gas exchange unit or membrane oxygenator, a fluids delivery unit, an amniotic fluid bed, and a human machine interface. In some embodiments, the artificial placenta and amniotic bed systems, devices, and methods described herein may improve survival rates and minimize long-term disabilities in preterm, gestational-age, newborns. In some embodiments, the extracorporeal systems, devices, and methods comprise an artificial network through which oxygen and nutrient-rich blood may flow into a fetus (residing in an amniotic fluid bed), while carbon dioxide and wastes may be removed, thus re-establishing a form of intrauterine placental circulation.

Several approaches to produce, isolate, and characterize exosomes recovered from a cultivated placenta or a portion thereof are provided. The alternatives described herein facilitate the production, isolation, and characterization of exosomes, which can be used as biotechnological tools and therapeutics. Also provided herein are populations of exosomes derived from placenta organ culture or culture of portions of the placenta. Also provided are compositions comprising the populations of exosomes and methods of their use for the treatment of subjects.

The present invention relates to a conditioned medium (CM) which is obtained by culturing, in a liquid culture medium, placental mesenchymal stem cells isolated from the placental tissue of pregnant women who not affected by preeclampsia. The conditioned medium of the present invention includes at least IL-6, IL-8 and MCP-1 proteins. The conditioned medium of the present invention is effective for the therapeutic treatment of preeclampsia.

Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food.